PMID- 31147451
OWN - NLM
STAT- MEDLINE
DCOM- 20200729
LR  - 20211204
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 39
IP  - 6
DP  - 2019 Jun 28
TI  - Combining use of Phillyrin and autophagy blocker alleviates laryngeal squamous 
      cell carcinoma via AMPK/mTOR/p70S6K signaling.
LID - BSR20190459 [pii]
LID - 10.1042/BSR20190459 [doi]
AB  - Phillyrin (PHN), one of the major active constituents of Forsythia suspensa and 
      F. koreana, has been reported to produce antioxidant, antibacterial, anti-obesity 
      and anti-inflammatory effects. However, no study has demonstrated the role of PHN 
      in laryngeal squamous cell carcinoma (LSCC). We aimed to investigate the effects 
      of PHN on the proliferation and apoptosis of HEp-2 cells. In the present study, 
      PHN alone showed little effect on HEp-2 cell proliferation and apoptosis. 
      Subsequent tests showed that PHN could largely enhance the level of autophagy on 
      HEp-2 cells. Combining use of PHN and autophagy blockers including 
      3-methyladenine (3-MA) and chloroquine (CQ) significantly inhibited HEp-2 cell 
      proliferation in a dose- and time-dependent manner and induced apoptosis after 24 
      h in a dose-dependent manner. Additionally, we found that the possible underlying 
      molecular mechanism of PHN-induced autophagy might be through the 
      AMPK/mTOR/p70S6K signaling pathway. Taken together, our study indicates that 
      combining use of PHN and autophagy blockers may serve as a novel strategy in LSCC 
      treatment.
CI  - (c) 2019 The Author(s).
FAU - Wang, Da-Hua
AU  - Wang DH
AUID- ORCID: 0000-0002-7841-4989
AD  - Department of Otolaryngology, Xuzhou Municipal Hospital Affiliated with Xuzhou 
      Medical University, Xuzhou 221002, China jack_dahua_wang@163.com.
FAU - He, Xi
AU  - He X
AD  - Department of Dermatology, Xuzhou Municipal Hospital Affiliated with Xuzhou 
      Medical University, Xuzhou 221002, China.
FAU - He, Qing
AU  - He Q
AD  - Department of Neurology, Xuzhou Municipal Hospital Affiliated with Xuzhou Medical 
      University, Xuzhou 221002, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190620
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (Glucosides)
RN  - 5142-23-4 (3-methyladenine)
RN  - 886U3H6UFF (Chloroquine)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - JAC85A2161 (Adenine)
RN  - VE9P4964MG (phillyrin)
SB  - IM
MH  - AMP-Activated Protein Kinases/*metabolism
MH  - Adenine/*analogs & derivatives/pharmacology
MH  - Apoptosis/drug effects
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Chloroquine/*pharmacology
MH  - Glucosides/*pharmacology
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Ribosomal Protein S6 Kinases, 70-kDa/*metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC6616054
OTO - NOTNLM
OT  - 3-methyladenine
OT  - Phillyrin
OT  - autophagy
OT  - chloroquine
OT  - laryngeal squamous cell carcinoma
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2019/05/31 06:00
MHDA- 2020/07/30 06:00
PMCR- 2019/06/20
CRDT- 2019/06/01 06:00
PHST- 2019/02/23 00:00 [received]
PHST- 2019/05/07 00:00 [revised]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2020/07/30 06:00 [medline]
PHST- 2019/06/01 06:00 [entrez]
PHST- 2019/06/20 00:00 [pmc-release]
AID - BSR20190459 [pii]
AID - 10.1042/BSR20190459 [doi]
PST - epublish
SO  - Biosci Rep. 2019 Jun 20;39(6):BSR20190459. doi: 10.1042/BSR20190459. Print 2019 
      Jun 28.